Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enlivex ( (ENLV) ) has issued an announcement.
On August 18, 2025, Enlivex Therapeutics Ltd. announced the posting of an updated investor presentation on its website, highlighting the Phase IIa results of their Allocetra therapy for knee osteoarthritis. The study identified a favorable safety profile and positive effects, with high responders representing over 50% of the knee osteoarthritis market. This finding supports the company’s hypothesis that a distinct responder group can be effectively targeted, potentially enhancing their market positioning and offering significant implications for stakeholders.
The most recent analyst rating on (ENLV) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage pharmaceutical company based in Israel, focusing on the development of Allocetra, a universal, off-the-shelf cell therapy. This therapy is designed to reprogram macrophages into their homeostatic state for the treatment of inflammatory diseases, addressing a substantial market need in inflammatory and autoimmune conditions.
Average Trading Volume: 239,616
Technical Sentiment Signal: Buy
Current Market Cap: $43.41M
For a thorough assessment of ENLV stock, go to TipRanks’ Stock Analysis page.